Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital

Acta Oncologica

Volumn 53, Issue 7, 2014, Pages 975-980

  Van Erning, Felice N ^a   Bernards, Nienke ^a,b   Creemers, Geert Jan ^b   Vreugdenhil, Art ^c   Lensen, Chantal J P A ^d   Lemmens, Valery E P P ^a,e  

^a Eindhoven Cancer Registry   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d BERNHOVEN HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COMORBIDITY; DISEASE FREE SURVIVAL; FEMALE; HOSPITAL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARD; CANCER ADJUVANT THERAPY; CANCER REGISTRY; COLON RESECTION; CONTROLLED STUDY; GROUPS BY AGE; OUTCOME ASSESSMENT; AGE; COLONIC NEOPLASMS; EPIDEMIOLOGY; NETHERLANDS; PATHOLOGY; RISK; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HOSPITALS; HUMANS; MALE; NETHERLANDS; ODDS RATIO; ORGANOPLATINUM COMPOUNDS;

EID: 84903265572     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.878470     Document Type: Letter

References (19)

1. Twelves C, Wong A, Nowacki M P, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer . New Engl J Med 2005; 352: 2696-704.
2. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial . J Clin Oncol 2009; 27: 3109-16.
3. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07 . J Clin Oncol 2007; 25: 2198-204.
4. Schrag D, Cramer LD, Bach PB, Begg CB . A ge and adjuvant chemotherapy use after surgery for stage III colon cancer . J Natl Cancer Inst 2001; 93: 850-7.
5. van Steenbergen L N, Rutten H J, Creemers G J, Pruijt J F, Coebergh JW, Lemmens VE . Large age and hospitaldependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands . Ann Oncol 2010; 21: 1273-8.
6. van Steenbergen LN, Lemmens VE, Rutten HJ, Wymenga AN, Nortier JW, Janssen-Heijnen ML . Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands . Ann Oncol 2012; 23: 2805-11.
7. Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer . J Clin Oncol 2012; 30: 972-9.
8. Panchal J M, Lairson D R, Chan W, Du X L . Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer . Clin Colorectal Cancer 2013; 12: 113-21.
9. Sanoff H K, Carpenter WR, Martin C F, Sargent D J, Meyerhardt JA, Sturmer T, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin- containing adjuvant chemotherapy for stage III colon cancer . J Natl Cancer Inst 2012; 104: 211-27.
10. Lund J L, Sturmer T, Sanoff H K, Brookhart A, S andler R S, Warren JL . Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients . Cancer 2013; 119: 2038-47.
11. Panchal J M, Lairson D R, Chan W, Du X L . Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer . Clin Colorectal Cancer 2013; 12: 113-21.
12. Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI . Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women . Cancer 2009; 115: 3848-57.
13. Goldberg R M, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer . J Clin Oncol 2006; 24: 4085-91.
14. Sanoff H K, Carpenter W R, Sturmer T, Goldberg RM, Martin CF, Fine JP, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years . J Clin Oncol 2012; 30: 2624-34.
15. Hsiao F Y, Mullins C D, Onukwugha E, Pandya N, Hanna N . Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: A "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data . J Am Geriatr Soc 2011; 59: 1717-23.
16. Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial . J Clin Oncol 2012; 30: 3353-60.
17. van Gils C W, Koopman M, Mol L, Redekop WK, Uyl-de Groot CA, Punt CJ . Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands . Acta Oncol 2012; 51: 57-64.
18. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer . J Clin Oncol 2011; 29: 3255-62.
19. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses . J Clin Oncol 2011; 29: 3768-74.